SINOVAC and Bogotá Present BogotáBio, Colombia's First Public Vaccine Manufacturing Facility

The company's launch ceremony was led by Sinovac's CEO and Chairman, Mr. Weidong Yin, alongside Bogotá's Mayor, Claudia López.

December 18, 2023, Bogotá, Colombia – Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a renowned global provider of bio-pharmaceutical products, announced today its partnership with the District of Bogotá in establishing BogotáBio, a company focused on vaccine and biologics development and production, marking a significant milestone in the country's pursuit of health sovereignty.

The launch ceremony presided over by Sinovac's Chairman, President & CEO , Mr. Weidong Yin, and Bogotá's Mayor, Claudia López, marked the official start of this pioneering enterprise in Colombia. The company's incorporation was formalized, unveiling its corporate identity, symbolizing a steadfast commitment to public health and Colombia's technological and industrial advancement.

Mr. Yin noted that the COVID-19 pandemic has made all countries fully realize the importance of vaccines for national security and people's health and Bogotá Government made the choice of SINOVAC as a strategic partner came after evaluating proposals from 15 biopharmaceutical companies around the world. Bogotá Government and SINOVAC have formulated a 10-year development plan and will establish a vaccine production base which can produce multiple types of vaccines through technical cooperation."We will carry out project construction and personnel training in accordance with the most advanced international standards, in order to achieve localized production of vaccines in Colombia as soon as possible. We firmly believe that this project will benefit the people of Colombia."

Mayor López highlighted the collaboration's importance, emphasizing its contribution to scientific progress and independence in producing essential vaccines: "Thanks to the Chinese government and Sinovac for having trusted in Bogota, for believing in us and in Colombia. Thank you Mr. Yin for being here with us with your team. BogotáBio is a wonderful legacy that we leave to Colombia in terms of sanitary sovereignty".

BogotáBio: An Innovation and Progress Platform for Colombia

On May 31, 2023, following a rigorous selection process, Sinovac was appointed as the strategic partner for the District of Bogotá. This enterprise will not only manufacture vaccines against hepatitis A, varicella, and polio but will also develop capacities for future vaccines, preparing the country for forthcoming health emergencies, generating employment, and nurturing Colombian scientific talent.

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a global biopharmaceutical company headquartered in China. Guided by its mission to “Supply Vaccines to Eliminate Human Diseases,” the Company is dedicated to the research, development, manufacturing and supply of vaccines and related biological products, providing vaccine products and related solutions for disease prevention and control worldwide.

SINOVAC has a diversified vaccine portfolio across multiple disease areas, including influenza, viral hepatitis, varicella, hand, foot and mouth disease (HFMD), poliomyelitis, rabies, tetanus, and pneumococcal disease. Three of SINOVAC's vaccines have been prequalified by the World Health Organization: the inactivated hepatitis A vaccine Healive®, the Sabin-strain inactivated poliomyelitis  vaccine (sIPV), and the live attenuated varicella vaccine.

SINOVAC has extensive experience in vaccine research, development and commercialization for emerging infectious diseases and public health emergencies. The Company initiated vaccine R&D in response to major public health threats, including SARS, H5N1, H1N1, and COVID-19, and developed the world's first inactivated SARS vaccine (with Phase I clinical trials completed), China's first inactivated pandemic influenza vaccine against H5N1 (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the world's most widely used inactivated COVID-19 vaccine. Beyond its marketed portfolio, SINOVAC continues to advance its R&D pipeline, spanning combination vaccines, recombinant protein vaccines, mRNA technologies, antibody-based products, and other next-generation technologies and product platforms, while expanding its capabilities in disease prevention and biopharmaceuticals.

With a long-standing commitment to innovation and global health, SINOVAC continues to deepen collaboration with research institutions, international organizations, and local partners while expanding its global presence. Through technological collaboration, localized production, and industrial partnerships, the Company aims to improve access to high-quality vaccines across regions, better address local disease prevention and healthcare needs, and strengthen preparedness for future public health challenges.

For more information, please see the Company's website at www.sinovac.com.